MINNEAPOLIS – February 13, 2014 – Medtronic, Inc. 1, 2016 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the FDA approval of the Enlitesensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system, a market-leading CGM system that enables healthcare providers to obtain a more complete picture of glucose control for the diabetes patients they treat. With over 38,000 employees worldwide, we’re creating technologies that treat chronic disease in new ways so people can live better, longer. Admittedly, we always jump at the chance to gather in person for a DOC pow-wow — yet we were once again somewhat leery of what the day would entail, especially since the agenda was kept secret until the last second (when we arrived by multiple cars from our downtown LA hotel to Medtronic’s HQ in Northridge, CA). The INS SENSITIVITY 1 screen appears. It also incorporates a new insulin pump design to provide convenient diabetes management with a simple user interface, full-color screen, waterproofing3 and remote bolus. to approximately 4 p.m.
The primary study endpoint will be sensor accuracy with the minimum calibration requirements (every 12 hours after the second calibration). We can accelerate and advance our ability to create meaningful innovations – but we will only succeed with the right people on our team. As PR Manager, that means her lips must remain sealed. Help us shape the future